Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor
- PMID: 10100711
Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor
Abstract
Using an immunocytological approach, we previously showed that disseminated cancer cells are frequently found in peritoneal cavity and bone marrow samples of gastrointestinal and pancreatic cancer patients. Recently, we demonstrated that the detection of isolated tumor cells could serve as a new prognostic factor in gastric and colorectal cancer. Thus far, no conclusive data concerning the clinical implication of minimal residual disease in pancreatic cancer exist. In this study, we investigated peritoneal lavage and bone marrow samples of 80 pancreatic cancer patients to determine the predictive value of immunocytologically detected disseminated tumor cells. Therefore, immunocytological findings were correlated with the clinical follow-up data (median observation time, 10.7 months; range, 2-61 months), and the findings in peritoneal cavity and bone marrow samples were compared. Fifty-two % of the patients showed minimal residual disease at least in one compartment (39% positive lavage and 38% positive bone marrow samples). The detection rate of isolated tumor cells increased in parallel to the tumor stage. The presence of tumor cells in the peritoneal cavity significantly correlated with the survival time of the patients (P = 0.0035). In bone marrow samples, a strong trend was seen (P = 0.06). The evaluation of both compartments increased the number of positive patients and resulted in a highly significant correlation: all patients who were positive in at least one compartment died within 18 months, whereas negative patients showed a 5-year survival rate of 30% (P<0.0001). We recommend immunocytological investigation of peritoneal cavity and bone marrow samples as a new prognostic marker in pancreatic cancer patients.
Similar articles
-
[Immunocytologic detection of disseminated tumor cells in the peritoneal cavity and bone marrow in patients with pancreatic carcinoma].Chirurg. 1994 Dec;65(12):1111-5. Chirurg. 1994. PMID: 7851144 German.
-
[Immunocytologic detection of micro-metastatic cells in patients with gastrointestinal tumors].Zentralbl Chir. 1995;120(2):116-22. Zentralbl Chir. 1995. PMID: 7709662 German.
-
Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients.Surgery. 2001 May;129(5):537-46. doi: 10.1067/msy.2001.113819. Surgery. 2001. PMID: 11331445
-
Microscopic tumor cell dissemination in gastric cancer.Surg Today. 2004;34(2):101-6. doi: 10.1007/s00595-003-2666-4. Surg Today. 2004. PMID: 14745607 Review.
-
Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.Cancer Treat Rev. 2000 Feb;26(1):53-65. doi: 10.1053/ctrv.1999.0150. Cancer Treat Rev. 2000. PMID: 10660491 Review.
Cited by
-
Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer.J Korean Med Sci. 2011 Jul;26(7):881-5. doi: 10.3346/jkms.2011.26.7.881. Epub 2011 Jun 20. J Korean Med Sci. 2011. PMID: 21738340 Free PMC article.
-
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival.J Cancer Res Clin Oncol. 2005 Oct;131(10):669-76. doi: 10.1007/s00432-005-0008-1. Epub 2005 Sep 1. J Cancer Res Clin Oncol. 2005. PMID: 16136352 Free PMC article.
-
Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.Oncotarget. 2015 May 30;6(15):13402-15. doi: 10.18632/oncotarget.2830. Oncotarget. 2015. PMID: 25596746 Free PMC article.
-
Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction.J Gastrointest Surg. 2007 Dec;11(12):1598-605; discussion 1605-6. doi: 10.1007/s11605-007-0283-z. Epub 2007 Sep 19. J Gastrointest Surg. 2007. PMID: 17879123
-
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1. Invest New Drugs. 2008. PMID: 18379729 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Medical